ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.

Vergote I, Perez Fidalgo A, Valabrega G, Monk BJ, Herzog T, Cibula D, Colombo N, Pothuri B, Sehouli J, Korach J, Barlin J, Papadimitriou CA, van Gorp T, Richardson D, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL

Open source

DOI: 10.1136/ijgc-2024-005412
Published: 2024 Aug 5
Container: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/ijgc-2024-005412,
  title = {ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.},
  author = {Vergote I and Perez Fidalgo A and Valabrega G and Monk BJ and Herzog T and Cibula D and Colombo N and Pothuri B and Sehouli J and Korach J and Barlin J and Papadimitriou CA and van Gorp T and Richardson D and McCarthy M and Antill Y and Mirza MR and Li K and Kalyanapu P and Slomovitz B and Coleman RL},
  year = {2024},
  journal = {International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  doi = {10.1136/ijgc-2024-005412},
  url = {https://doi.org/10.1136/ijgc-2024-005412}
}

RIS

TY  - JOUR
TI  - ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
AU  - Vergote I
AU  - Perez Fidalgo A
AU  - Valabrega G
AU  - Monk BJ
AU  - Herzog T
AU  - Cibula D
AU  - Colombo N
AU  - Pothuri B
AU  - Sehouli J
AU  - Korach J
AU  - Barlin J
AU  - Papadimitriou CA
AU  - van Gorp T
AU  - Richardson D
AU  - McCarthy M
AU  - Antill Y
AU  - Mirza MR
AU  - Li K
AU  - Kalyanapu P
AU  - Slomovitz B
AU  - Coleman RL
PY  - 2024
JO  - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
DO  - 10.1136/ijgc-2024-005412
UR  - https://doi.org/10.1136/ijgc-2024-005412
ER  -

APA

I, V., A, P. F., G, V., BJ, M., T, H., D, C., N, C., B, P., J, S., J, K., J, B., CA, P., T, V. G., D, R., M, M., Y, A., MR, M., K, L., P, K., B, S., & RL, C. (2024). ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. https://doi.org/10.1136/ijgc-2024-005412

Source records

pubmed · retrieved 2026-09-26T01:29:39.578Z
europe-pmc · retrieved 2026-09-26T01:29:39.594Z